High intratumoral Galectin‐1 expression predicts adverse outcome in ALK‐ ALCL and CD30+ PTCL‐NOS

Galectin‐1 (Gal‐1) has been associated with adverse prognosis in several cancers including lymphoma entities with CD30 expression. However, Gal‐1 expression has not been systematically assessed in pe…

Read the full article here

Related Articles